Patents Represented by Attorney, Agent or Law Firm Paul J. Gaylo
-
Patent number: 6087154Abstract: This invention describes a rhesus receptor, designated the rhesus Y1 receptor, having affinity for neuropeptide Y, pancreatic polypeptide, and peptide YY. This invention also encompasses nucleic acids encoding this receptor, or a fragment thereof, as well as methods employing this receptor and the nucleic acid compounds.Type: GrantFiled: March 20, 1998Date of Patent: July 11, 2000Assignee: Eli Lilly and CompanyInventors: Melvyn Baez, Carolyn Ann George
-
Patent number: 6075039Abstract: A pharmaceutical compound of the formula ##STR1## in which X is --CR'R"-- or --C(O)-- where R' and R" are each hydrogen, C.sub.1-6 alkyl or optionally substituted phenyl, Y is oxygen or sulphur, R.sup.1, R.sup.2 and R.sup.7 are each selected from halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl, nitro, cyano, amino, phenyl, phenoxy, benzyl, benzyloxy, acylamino, C.sub.1-4 alkylsulphonylamino, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulphonyl, carboxamido, sulphonamido, hydroxy, methylenedioxy, carboxy, and heteroaryl, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are each hydrogen, C.sub.1-6 alkyl or optionally substituted phenyl, n, m and p are each 0, 1, 2 or 3;or a salt or ester thereof.Type: GrantFiled: June 24, 1997Date of Patent: June 13, 2000Assignee: Eli Lilly and Company LimitedInventors: Peter Thaddeus Gallagher, Martin Victor Miles, William Martin Owton, Colin William Smith
-
Patent number: 6030992Abstract: This invention provides methods for the treatment or prevention of sleep apnea in a mammal which compris administering to a mammal in need thereof an effective amount of a substituted benzimidazole, or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: August 27, 1998Date of Patent: February 29, 2000Assignee: Eli Lilly and CompanyInventors: Bruce D. Gitter, Smriti Iyengar
-
Patent number: 6025379Abstract: This invention provides methods for the treatment or prevention of interstitial cystitis or urethral syndrome in a mammal which comprise administering to a mammal in need thereof an effective amount of a substituted benzimidazole, or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: August 25, 1998Date of Patent: February 15, 2000Assignee: Eli Lilly and CompanyInventors: Smriti Iyengar, Mark A. Muhlhauser, Karl B. Thor
-
Patent number: 6025178Abstract: The invention provides a novel phospholipase A.sub.2 enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.Type: GrantFiled: March 28, 1997Date of Patent: February 15, 2000Assignee: Eli Lilly and CompanyInventors: Xue-Chiou C. Choiu, Ruth M. Kramer, Richard T. Pickard, John D. Sharp, Beth A. Strifler
-
Patent number: 6017697Abstract: This invention describes a novel human glutamate receptors, designated mGluR2. This invention also encompasses nucleic acids encoding this receptor, or a fragment thereof, as well as methods employing this receptor and the nucleic acid compounds.Type: GrantFiled: November 14, 1994Date of Patent: January 25, 2000Assignee: Eli Lilly and CompanyInventors: James Paul Burnett, Jr., Nancy Gail Mayne, Robert Leon Sharp, Yvonne Marie Snyder
-
Patent number: 6017930Abstract: This invention provides methods for the treatment or prevention of interstitial cystitis or urethral syndrome in a mammal which comprise administering to a mammal in need thereof an effective amount of a compound of formula (I), where R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen, methyl, methoxy, chloro, and trifluoromethyl, with the proviso that no more than one of R.sup.1 and R.sup.2 can be hydrogen; and Y is (1), (2), (3), (4), (5), (6), N--R.sup.a, or CH--NR.sup.b R.sup.c, where R.sup.a, R.sup.b, and R.sup.c are independently selected from the group consisting of hydrogen and C.sub.1 -C.sub.6 alkyl; or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: August 25, 1998Date of Patent: January 25, 2000Assignee: Eli Lilly and CompanyInventors: Smriti Iyengar, Mark A. Muhlhauser, Karl B. Thor
-
Patent number: 6008041Abstract: The present invention provides the cDNA sequence encoding bovine dipeptidylaminopeptidase 1. The invention demonstrates that bovine DAP 1 coded by a single cDNA. The mature protein is derived from a single polypeptide consisting of a signal peptide, and a major polypeptide which is processed to generate the a subunit, b subunit and g subunit.Type: GrantFiled: May 2, 1997Date of Patent: December 28, 1999Assignee: Eli Lilly and CompanyInventors: Christopher Carl Frye, Charles Lee Hershberger, Haichao Zhang
-
Patent number: 6001837Abstract: This invention provides methods for the treatment or prevention of sleep apnea in a mammal which comprise administering to a mammal in need thereof an effective amount of a compound of formula (I) where R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen, methyl, methoxy, chloro, and trifluoromethyl, with the proviso that no more than one of R.sup.1 and R.sup.2 can be hydrogen; and Y is (a), (b), (c), (d), (e), (f), N-R.sup.a, or CH-NR.sup.b R.sub.c, where R.sup.a, R.sup.b, and R.sup.c are independently selected from the group consisting of hydrogen and C.sub.1 -C.sub.6 alkyl; or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: August 27, 1998Date of Patent: December 14, 1999Assignee: Eli Lilly and CompanyInventors: Bruce D. Gitter, Smriti Iyengar
-
Patent number: 5972888Abstract: This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein. This invention also describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.Type: GrantFiled: October 23, 1997Date of Patent: October 26, 1999Assignee: Eli Lilly and CompanyInventors: Juliana Maude Bue-Valleskey, Mark Louis Heiman, Thomas Wesley Stephens, Frank C. Tinsley
-
Patent number: 5972675Abstract: The present invention describes a protein kinase which catalyzes the in phosphorylation of BRCA-1 protein. The present invention also describes the use of the BRCA-1 protein kinase as a molecular target for therapeutic intervention and/or as a therapeutic tool for diagnosing and treating breast and/or ovarian cancer.Type: GrantFiled: January 17, 1997Date of Patent: October 26, 1999Assignee: Eli Lilly and CompanyInventors: Richard P. Beckmann, Teresa F. Burke, Kimberly S. Cocke, Stephanie J. Lemke
-
Patent number: 5958960Abstract: Compounds of the formula ##STR1## in which R.sup.1 and R.sup.2 are as defined in the specification, and non-toxic metabolically labile ester and amides thereof are useful as modulators of metabotropic glutamate receptor function.Type: GrantFiled: May 13, 1998Date of Patent: September 28, 1999Assignee: Eli Lilly and CompanyInventors: Steven Marc Massey, James Allen Monn, Matthew John Valli
-
Patent number: 5891875Abstract: This invention provides methods of treating a physiological disorder associated with an excess of tachykinins in a mammal which comprises administering to a mammal in need of said treatment a compound selected from a series of substituted morpholines. This invention also provides a series of novel substituted morpholines as well as pharmaceutical formulations employing these substituted morpholines.Type: GrantFiled: May 20, 1997Date of Patent: April 6, 1999Assignee: Eli Lilly and CompanyInventors: Philip A. Hipskind, Karen L. Lobb
-
Patent number: 5846973Abstract: This invention provides methods of inhibiting pulmonary hypertensive disease which comprise administering to a mammal in need thereof a compound having activity as a tachykinin receptor antagonist.Type: GrantFiled: May 23, 1997Date of Patent: December 8, 1998Assignee: Eli Lilly and CompanyInventors: Donald Richard Gehlert, Mitchell Irvin Steinberg
-
Patent number: 5840509Abstract: The present invention provides for a novel ICE related protease and nucleic acids coding same. The present invention also provides a method to isolate an ICE related protease and related DNA compounds encoding this protease. The present invention further comprises a method using said protease to screen for inhibitors of apoptosis. Additionally, the invention further comprises a method of using said inhibitors of apoptosis in the treatment in human patients with the acquired disease states of brain ischemia, stroke, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), head trauma, or other neurodegenerative disorders.Type: GrantFiled: July 9, 1997Date of Patent: November 24, 1998Assignee: Eli Lilly and CompanyInventors: Binhui Ni, Marc Paul, Xin Wu
-
Patent number: 5827879Abstract: This invention provides certain substituted 2,3-dihydrobenzofurylsulfonamide derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these benzenesulfonamide derivatives in combination with a carrier.Type: GrantFiled: October 3, 1997Date of Patent: October 27, 1998Assignee: Eli Lilly and CompanyInventors: William J. Ehlhardt, James E. Ray, John E. Toth
-
Patent number: 5824496Abstract: The present invention provides a method for preventing the accumulation of aberrant expression vectors during fermentation processes which rely on the expression of an expression vector coded gene for production of a polypeptide product of interest. Antibiotics are added at approximately the time at which product expression begins.Type: GrantFiled: August 10, 1995Date of Patent: October 20, 1998Assignee: Eli Lilly and CompanyInventor: William L. Muth
-
Patent number: 5814503Abstract: The present invention provides novel fusion proteins comprising cyclins and CDKs. A preferred embodiment of the invention provides fusion proteins comprising human cyclin D1 and human CDK4. The fusion proteins of the invention optionally contain modifications, which facilitate their purification. Addition of histidine residues to selected constructs allows purification via immobilized metal affinity chromatography. Antigenic determinants allowing monoclonal antibody-based affinity chromatography purification are provided in selected embodiments of the invention. Protease cleavage sites are incorporated in selected constructs to allow cleavage of the regions incorporated in the cyclin-CDK fusion proteins for purification. Additional modifications which facilitate purification include strepavadin binding domains and antigenic determinants for antibody affinity chromatography.Type: GrantFiled: December 19, 1996Date of Patent: September 29, 1998Assignee: Eli Lilly and CompanyInventors: Steven Kovacevic, Keith A. Otto, Ramachandra N. Rao
-
Patent number: 5792760Abstract: This invention provides a series of substituted bisindole propanamides which are useful as tachykinin receptor antagonists and as serotonin agonists. This invention also provides methods for the treatment of related disorders as well as pharmaceutical formulations which employ these novel compounds.Type: GrantFiled: April 23, 1997Date of Patent: August 11, 1998Assignee: Eli Lilly and CompanyInventors: Philip A. Hipskind, Karen L. Lobb
-
Patent number: 5776931Abstract: This invention provides a series of substituted 1H-naphth?2,3-d!imidazoles which are useful in treating a condition associated with an excess of neuropeptide Y. This invention also provides methods employing these substituted 1H-naphth?2,3-d!imidazoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these compounds.Type: GrantFiled: January 9, 1997Date of Patent: July 7, 1998Assignee: Eli Lilly and CompanyInventors: Anne Marie Nunes, Hamideh Zarrinmayeh